Passive immunotherapy in Alzheimer’s disease: biomarkers, biological staging, and emerging therapeutic strategies
Alzheimer’s disease (AD) is increasingly defined and staged using biological markers rather than clinical phenotype alone, reflecting a major shift toward biomarker-based diagnosis and therapeutic stratification. In parallel, passive immunotherapies targeting amyloid-beta (Aβ) and tau have introduced a new disease-modi...